ICON Public Limited (NASDAQ:ICLR) Shares Sold by Schechter Investment Advisors LLC

Schechter Investment Advisors LLC trimmed its position in ICON Public Limited (NASDAQ:ICLR) by 9.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,048 shares of the medical research company’s stock after selling 440 shares during the period. Schechter Investment Advisors LLC’s holdings in ICON Public were worth $1,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Bruce G. Allen Investments LLC acquired a new stake in ICON Public during the 4th quarter worth about $25,000. Farther Finance Advisors LLC grew its position in shares of ICON Public by 102.7% during the 2nd quarter. Farther Finance Advisors LLC now owns 150 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 76 shares during the period. First Horizon Advisors Inc. grew its position in shares of ICON Public by 10.9% during the 1st quarter. First Horizon Advisors Inc. now owns 551 shares of the medical research company’s stock valued at $118,000 after acquiring an additional 54 shares during the period. Alpha Paradigm Partners LLC acquired a new stake in shares of ICON Public during the 3rd quarter valued at about $123,000. Finally, NBC Securities Inc. acquired a new stake in shares of ICON Public during the 3rd quarter valued at about $174,000. 95.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ICLR has been the topic of several research analyst reports. Mizuho lifted their price objective on ICON Public from $315.00 to $346.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Barclays lifted their price objective on ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Citigroup lifted their price objective on ICON Public from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Monday, December 11th. Evercore ISI lifted their price objective on ICON Public from $325.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, February 23rd. Finally, JPMorgan Chase & Co. boosted their target price on ICON Public from $295.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $312.64.

ICON Public Trading Down 0.1 %

Shares of ICON Public stock opened at $329.50 on Thursday. ICON Public Limited has a 12-month low of $181.92 and a 12-month high of $344.77. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.40. The stock has a market cap of $27.18 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 1.54 and a beta of 1.15. The company has a 50-day moving average of $300.71 and a two-hundred day moving average of $273.83.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, topping analysts’ consensus estimates of $3.27 by $0.13. ICON Public had a net margin of 7.54% and a return on equity of 11.42%. The business had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.08 billion. On average, research analysts anticipate that ICON Public Limited will post 14.4 EPS for the current fiscal year.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.